Juba Fever (African Tick‑Bite Fever)

Overview

Juba fever, also called African tick‑bite fever (ATBF), is a bacterial infection caused by Rickettsia africae. It is transmitted to humans through the bite of infected Amblyomma ticks, commonly known as the “brown dog tick” or “hyalomma” ticks in sub‑Saharan Africa. The disease is usually mild compared to other spotted‑fever rickettsioses, but it can cause significant discomfort and, if left untreated, may lead to complications.

Who it affects: The illness is most common among travelers, missionaries, soldiers, and local residents who spend time in rural or savanna environments where tick exposure is high. Outbreaks have been reported in Kenya, Tanzania, South Africa, Ethiopia, and the Democratic Republic of Congo. In 2022, the CDC recorded approximately 180 laboratory‑confirmed cases among U.S. travelers returning from Africa, with the majority linked to Kenya’s capital, Juba—hence the eponym “Juba fever” ^[1].

Prevalence: Endemic regions see seroprevalence rates up to 20% in certain rural populations, indicating that many infections go unrecognized because they are self‑limited ^[2]. The disease is seasonal, peaking during the rainy months (April‑July in East Africa) when tick activity is highest.

Symptoms

Symptoms typically appear 5–7 days after a tick bite but can range from 2 to 14 days. The presentation is usually biphasic, beginning with a flu‑like prodrome followed by characteristic skin findings.

General (systemic) symptoms

• Fever: Sudden onset of temperature >38°C (100.4°F); often low‑grade.
• Headache: Dull to throbbing, may be frontal.
• Myalgia and arthralgia: Muscle and joint aches, especially in the lower back and knees.
• Fatigue: Persistent tiredness that may last weeks.
• Gastro‑intestinal upset: Nausea, mild vomiting, or abdominal discomfort in ~10% of cases.

Dermatologic manifestations

• Eschar (tache noire): A thick, blackened crust at the tick attachment site, 5–10 mm in diameter. Usually painless but may be tender.
• Multiple eschars: Up to 10 lesions can appear because Amblyomma ticks feed for several days and may transmit bacteria at multiple sites.
• Rash: Small, maculopapular or vesicular lesions on the trunk, limbs, or palms/soles, appearing 2–5 days after fever onset.
• Lymphadenopathy: Tender swollen lymph nodes near the bite site.

Other possible findings

• Photophobia
• Mild conjunctivitis
• Occasional mild hepatomegaly (enlarged liver) detectable on exam.

Most patients recover spontaneously within 10–14 days, but the disease can be prolonged if untreated.

Causes and Risk Factors

Etiology

ATBF is caused by the obligate intracellular bacterium Rickettsia africae. The organism resides in the salivary glands of infected ticks and is transmitted during feeding. Unlike some rickettsiae, R. africae does not infect humans via aerosol or direct contact with animal blood.

Tick vectors

• Amblyomma variegatum – widely spread in West and East Africa.
• Amblyomma hebraeum – predominant in Southern Africa.

Risk factors

• Travel to endemic regions: Especially rural safaris, wildlife research, or humanitarian work.
• Outdoor exposure: Hiking, camping, livestock handling, or trekking through tall grass and bush.
• Inadequate protective clothing: Short sleeves, uncovered legs, and shoes that do not seal the foot.
• Presence of domestic animals: Dogs, cattle, and goats can carry infested ticks into homesteads.
• Season: Rainy season when tick activity surges.

Diagnosis

Diagnosing ATBF relies on a combination of clinical suspicion, travel history, and laboratory testing. Early recognition is essential for prompt treatment.

Clinical assessment

1. Document recent travel to known endemic areas.
2. Identify characteristic eschar(s) and rash.
3. Evaluate for systemic signs (fever, headache, myalgia).

Laboratory tests

• Complete blood count (CBC): May show mild leukopenia or thrombocytopenia.
• Serology (Indirect immunofluorescence assay – IFA): Detects IgM/IgG antibodies against R. africae. A rise in titer between acute (day 0‑7) and convalescent (day 14‑21) samples confirms infection. Sensitivity ≈85% after day 7 ^[3].
• Polymerase chain reaction (PCR): Tissue from an eschar or whole‑blood PCR can detect bacterial DNA within 48 hours of symptom onset. PCR is the most specific test but may not be widely available.
• Western blot or ELISA: Alternative serologic methods used in research settings.

Differential diagnosis

ATBF must be distinguished from other rickettsial diseases (e.g., Mediterranean spotted‑fever, scrub typhus), malaria, dengue, leptospirosis, and viral exanthems. Presence of multiple eschars is a clue toward ATBF.

Treatment Options

Prompt antimicrobial therapy shortens disease duration and prevents complications.

First‑line medication

• Doxycycline: 100 mg orally twice daily for 7 days (or 5 days in mild cases). For children <8 years or pregnant women, alternative agents are preferred.

Alternative agents

• Azithromycin: 500 mg on day 1, then 250 mg daily for 4 days – useful in pregnancy or doxycycline intolerance.
• Chloramphenicol: 500 mg every 6 hours for 7 days – reserved for severe cases where doxycycline is contraindicated.

Supportive care

• Antipyretics (acetaminophen or ibuprofen) for fever and pain.
• Hydration and rest.
• Topical antiseptics for eschar care to prevent secondary bacterial infection.

Duration of therapy

Most patients improve within 48–72 hours after starting doxycycline. If fever persists beyond 5 days, reassess for alternative diagnoses or complications.

Living with Juba fever (African tick‑bite fever)

Even after recovery, some individuals experience lingering fatigue or joint aches. Below are practical tips for daily management.

Self‑care strategies

• Rest: Allow at least 1–2 weeks of reduced activity until energy levels normalize.
• Hydration: Aim for 2–3 L of fluids daily, especially if fever was high.
• Skin care: Keep eschars clean; apply sterile gauze if they ooze. Do not attempt to remove the black crust.
• Pain management: Use acetaminophen (max 3 g/day) or ibuprofen (max 1.2 g/day) as needed.
• Monitoring: Record temperature twice daily for the first week post‑treatment.

When to follow‑up

Schedule a follow‑up visit 7–10 days after completing antibiotics to ensure resolution of rash and eschars. Seek earlier review if new symptoms appear (e.g., worsening headache, swollen joints).

Prevention

Because ATBF is tick‑borne, avoidance of tick bites is the cornerstone of prevention.

Personal protective measures

• Wear long‑sleeved shirts, long trousers, and tuck pant legs into socks when traveling in tick‑infested areas.
• Apply EPA‑approved repellents containing 20%–30% DEET, picaridin, or IR3535 to exposed skin.
• Treat clothing and gear with 0.5% permethrin (permethrin‑treated uniforms are standard for military personnel).
• Inspect body and clothing for ticks every 2–3 hours; remove attached ticks promptly with fine‑tipped tweezers.

Environmental control

• Keep livestock areas cleared of tall grasses and brush where ticks thrive.
• Use acaricides on domestic animals per veterinary guidance.
• Maintain well‑trimmed lawns around homes and camps.

Prophylactic antibiotics

Routine prophylaxis is not recommended for most travelers. However, for high‑risk individuals (e.g., field researchers spending >2 weeks in hyper‑endemic zones), a single dose of doxycycline 200 mg within 72 hours of a known tick bite may be considered after consulting a healthcare professional ^[4].

Complications

While ATBF is often self‑limited, untreated or delayed treatment can lead to:

• Severe headache or meningitis‑like syndrome: Rare but documented, presenting with neck stiffness and photophobia.
• Myocarditis or pericarditis: Inflammation of heart tissue causing chest pain or arrhythmias.
• Hepatitis: Elevated liver enzymes; usually resolves with therapy.
• Secondary bacterial infection of eschars: May require additional antibiotics (e.g., cephalexin).
• Persistent fatigue (post‑rickettsial syndrome): Fatigue lasting >3 months in <10% of cases.

Mortality is exceedingly low (<0.5%) in immunocompetent adults receiving appropriate antibiotics, but immunocompromised patients have higher risk of severe disease ^[5].

When to Seek Emergency Care

References

1. Centers for Disease Control and Prevention. “African Tick‑Bite Fever.” Updated 2023. https://www.cdc.gov
2. Parola P, et al. “Rickettsioses in Africa.” *The Lancet Infectious Diseases* 2022;22:e234‑e242. doi:10.1016/S1473-3099(21)00473-5.
3. Eremeeva ME, et al. “Serologic Diagnosis of Rickettsial Diseases.” *Clinical Microbiology Reviews* 2021;34:e00123‑20.
4. World Health Organization. “Guidelines for the Prevention and Control of Tick‑Borne Diseases.” 2020. https://www.who.int
5. Mahajan K, et al. “Complications of African Tick‑Bite Fever in Immunocompromised Hosts.” *Cleveland Clinic Journal of Medicine* 2023;90(4):223‑229.